Shares of Esperion Therapeutics Inc (NASDAQ:ESPR) have been assigned a consensus recommendation of “Buy” from the fourteen ratings firms that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation, seven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $72.89.
A number of equities analysts recently issued reports on ESPR shares. Citigroup set a $73.00 target price on Esperion Therapeutics and gave the stock a “buy” rating in a report on Tuesday, May 28th. Stifel Nicolaus reiterated a “buy” rating on shares of Esperion Therapeutics in a report on Thursday, June 13th. BidaskClub upgraded Westport Fuel Systems from a “hold” rating to a “buy” rating in a report on Friday. Northland Securities set a $65.00 target price on Esperion Therapeutics and gave the stock a “buy” rating in a report on Friday, June 14th. Finally, ValuEngine cut WideOpenWest from a “hold” rating to a “sell” rating in a report on Friday, June 28th.
Shares of ESPR stock traded down $1.24 during trading hours on Friday, hitting $45.51. 584,283 shares of the company were exchanged, compared to its average volume of 405,493. The stock has a market capitalization of $1.26 billion, a price-to-earnings ratio of -6.04 and a beta of 1.72. Esperion Therapeutics has a fifty-two week low of $36.06 and a fifty-two week high of $60.99. The company’s 50 day simple moving average is $48.98.
Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported $3.07 EPS for the quarter, topping the consensus estimate of $0.64 by $2.43. The company had revenue of $145.42 million for the quarter, compared to analyst estimates of $69.35 million. During the same period last year, the business earned ($1.73) EPS. On average, equities analysts expect that Esperion Therapeutics will post -2.65 EPS for the current year.
In other news, CEO Timothy M. Mayleben acquired 5,000 shares of the firm’s stock in a transaction that occurred on Friday, June 28th. The stock was bought at an average price of $46.00 per share, with a total value of $230,000.00. Following the acquisition, the chief executive officer now owns 66,163 shares in the company, valued at approximately $3,043,498. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 7.70% of the company’s stock.
A number of hedge funds have recently bought and sold shares of ESPR. Hsbc Holdings PLC purchased a new position in Esperion Therapeutics during the 4th quarter valued at about $11,067,000. FMR LLC grew its holdings in Esperion Therapeutics by 43.8% during the 4th quarter. FMR LLC now owns 739,289 shares of the biopharmaceutical company’s stock valued at $34,007,000 after buying an additional 225,205 shares in the last quarter. Spark Investment Management LLC grew its holdings in Esperion Therapeutics by 72.1% during the 1st quarter. Spark Investment Management LLC now owns 390,900 shares of the biopharmaceutical company’s stock valued at $15,694,000 after buying an additional 163,800 shares in the last quarter. Rhenman & Partners Asset Management AB grew its holdings in Esperion Therapeutics by 35.5% during the 1st quarter. Rhenman & Partners Asset Management AB now owns 479,767 shares of the biopharmaceutical company’s stock valued at $19,263,000 after buying an additional 125,806 shares in the last quarter. Finally, Norges Bank purchased a new position in Esperion Therapeutics during the 4th quarter valued at about $5,536,000.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Recommended Story: LIBOR
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.